Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Exagen Inc (XGN)

Exagen Inc (XGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,159
  • Shares Outstanding, K 24,053
  • Annual Sales, $ 66,580 K
  • Annual Income, $ -19,950 K
  • EBIT $ -12 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.88
  • Price/Sales 0.96
  • Price/Cash Flow N/A
  • Price/Book 3.48

Options Overview Details

View History
  • Implied Volatility 624.05% (-173.77%)
  • Historical Volatility 72.90%
  • IV Percentile 93%
  • IV Rank 63.87%
  • IV High 933.06% on 02/18/26
  • IV Low 77.89% on 08/18/25
  • Expected Move (DTE 16) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 862
  • Open Int (30-Day) 901
  • Expected Range 3.00 to 3.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.19
  • Number of Estimates 3
  • High Estimate $-0.10
  • Low Estimate $-0.25
  • Prior Year $-0.20
  • Growth Rate Est. (year over year) +5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.59 +15.83%
on 03/30/26
3.79 -20.78%
on 03/10/26
-0.62 (-17.13%)
since 02/27/26
3-Month
2.59 +15.83%
on 03/30/26
6.75 -55.56%
on 01/09/26
-3.13 (-51.06%)
since 12/26/25
52-Week
2.59 +15.83%
on 03/30/26
12.23 -75.47%
on 10/27/25
-0.84 (-21.87%)
since 03/28/25

Most Recent Stories

More News
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Record full-year total revenue and AVISE ® CTD average selling price New biomarkers and sales force expansion drove over 11% full-year test volume growth CARLSBAD, Calif., March 10, 2026...

XGN : 3.00 (+13.21%)
Exagen Inc. to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conferences:...

XGN : 3.00 (+13.21%)
Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

CARLSBAD, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended December 31, 2025,...

XGN : 3.00 (+13.21%)
Exagen Inc. Announces Select Preliminary 2025 Financial Results

CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth...

XGN : 3.00 (+13.21%)
Exagen Inc. to Participate in Fourth Quarter Investor Conferences

CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor...

XGN : 3.00 (+13.21%)
Exagen Inc. Reports Strong Q3 2025 Results

CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30,...

XGN : 3.00 (+13.21%)
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of...

XGN : 3.00 (+13.21%)
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30,...

XGN : 3.00 (+13.21%)
KeyBanc Reaffirms Their Buy Rating on Exagen (XGN)

KeyBanc analyst Paul Knight maintained a Buy rating on Exagen today and set a price target of $15.00. The company’s shares closed yesterday at $11.04.Elevate Your Investing Strategy: Take advantage of...

XGN : 3.00 (+13.21%)
Exagen Inc. Reports Strong Q2 2025 Results

CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025,...

XGN : 3.00 (+13.21%)

Business Summary

Exagen Inc. is engaged in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases. It developed and commercialises testing products under AVISE brand. Exagen Inc. is based in Vista, California.

See More

Key Turning Points

3rd Resistance Point 3.50
2nd Resistance Point 3.26
1st Resistance Point 3.13
Last Price 3.00
1st Support Level 2.76
2nd Support Level 2.52
3rd Support Level 2.39

See More

52-Week High 12.23
Fibonacci 61.8% 8.55
Fibonacci 50% 7.41
Fibonacci 38.2% 6.27
Last Price 3.00
52-Week Low 2.59

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.